23rd June 2025
In a significant move to accelerate the Global fight against blood cancers and hard- to-treat solid tumours, renowned end-to-end biologics company Mabion have entered into a strategic development and manufacturing partnership with London based NovalGen, to bring their proprietary T-cell engager, NVG-222 to market for phase one of in-human clinical trials; with initial outcomes expected by H2 2026.
With the first batch drug released, this partnership signifies a pivotal moment in the development of next-generation immunotherapies, offering a potential new lifeline for cancer patients. Leveraging Mabion's progressive manufacturing and development capabilities to minimise risk in pharmaceutical production, the technology transfer, development and clinical compliance provides a platform for future collaboration on NovalGen’s pipeline of disruptive treatments in development, including promising candidates for both oncology and non-oncology indications.
Professor Amit Nathwani, Founder and CEO of NovalGen said:
The successful manufacture of NVG-222 marks a major milestone in our journey to bring safer, more effective immunotherapies to patients. Our collaboration with Mabion, a trusted CDMO partner, has been characterised by exceptional technical execution, a shared commitment to quality, and a mutual drive to deliver innovative therapies that truly impact patient lives. As we prepare for clinical trial initiation in the second half of 2025 and continue progressing our pipeline, especially in oncology and autoimmune indications, we look forward to expanding our partnership with Mabion to accelerate the delivery of transformative solutions for patients with high unmet medical need.
